Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease
DARU Journal of Pharmaceutical Sciences · 07.08.2026 · 34 (2)
DOI: 10.1007/s40199-026-00637-7 ↗Kurz gefasst
Metaanalyse in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 07.08.2026. Verfasst von Andrea Matteucci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ospedale San Filippo Neri, Rome, Italy. andrea.matteucci2@gmail.com. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Urinary Tract Infections, Diabetes Mellitus, Type 2, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established therapies across the cardiovascular–renal continuum. Although the excess risk of external genital infection is well recognized, the association between SGLT2 inhibition and urinary tract infection (UTI), particularly serious/complicated urinary infection, remains uncertain.
Methods
We conducted a systematic review and meta-analysis of randomized placebo-controlled trials of empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and bexagliflozin in adults with type 2 diabetes, chronic kidney disease, or heart failure. Co-primary urinary safety outcomes were any UTI and serious/complicated urinary infection, the latter defined using directly reported serious UTI endpoints or the closest reported severe urinary phenotype. Sensitivity analysis, subgroup analyses by drug and population, leave-one-out analyses, and exploratory meta-regression were performed.
Results
A total of 14 studies were included. For the primary any-UTI analysis, 11 studies contributed data, comprising 62,542 participants and 4,685 events. SGLT2 inhibitors were associated with a pooled RR of 1.14 (95% CI 0.99–1.32; P = 0.073), with substantial heterogeneity (I²=76.0%). In the prespecified sensitivity analysis excluding reconstructed CANVAS estimates, 10 studies comprising 52,400 participants and 4,019 events yielded a pooled RR of 1.08 (95% CI 1.00–1.18; P = 0.060), with lower heterogeneity (I²=23.3%). For the serious/complicated urinary infection analysis, 7 studies comprising 34,396 participants and 339 events were available. The pooled RR was 0.99 (95% CI 0.78–1.27; P = 0.960), with no detectable heterogeneity (I²=0.0%). No significant subgroup differences were observed by individual SGLT2 inhibitor or by clinical population.
Conclusions
SGLT2 inhibitors were not associated with a statistically significant increase in any UTI or serious/complicated UTI. These findings support a distinction between lower-grade urinary events and clinically severe urinary infection, and suggest that urinary safety concerns should not be considered equivalent to the established excess risk of external genital infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ospedale San Filippo Neri, Rome, Italy. andrea.matteucci2@gmail.com.
- Ospedale San Filippo Neri, Rome, Italy.
- University of Rome Tor Vergata, Rome, Italy.
- Ospedale Sandro Pertini, Rome, Italy.
- Santo Spirito Hospital, Casale Monferrato, Italy.
Zitieren
APA
Matteucci, A., Di Fusco, S. A., Bonanni, M., Castello, L., Aquilani, S., Fedele, S., Nardi, F., & Colivicchi, F. (2026). Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. DARU Journal of Pharmaceutical Sciences, 34(2). https://doi.org/10.1007/s40199-026-00637-7
Vancouver
Matteucci A, Di Fusco SA, Bonanni M, Castello L, Aquilani S, Fedele S, et al. Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. DARU Journal of Pharmaceutical Sciences. 2026;34(2). doi:10.1007/s40199-026-00637-7
BibTeX
@article{Matteucci2026,
author = {Matteucci, Andrea and Di Fusco, Stefania Angela and Bonanni, Michela and Castello, Lorenzo and Aquilani, Stefano and Fedele, Silvio and Nardi, Federico and Colivicchi, Furio},
title = {Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
volume = {34},
number = {2},
doi = {10.1007/s40199-026-00637-7}
}
EUVIMED